J Korean Ophthalmol Soc.  2017 Sep;58(9):1066-1073. 10.3341/jkos.2017.58.9.1066.

Female Hormone Factors Associated with Age-related Macular Degeneration in Menopausal Korean Women: KNHANES V

• Baek SK
• Lee YH

• KMID: 2390070
• DOI: http://doi.org/10.3341/jkos.2017.58.9.1066

Abstract

PURPOSE
To investigate whether endogenous and exogenous female hormone exposures were associated with risks for age-related macular degeneration (AMD) in postmenopausal women.
METHODS
This study included 4,479 postmenopausal females aged 45 years and older who completed the Korea National Health and Nutrition Examination Survey (KNHANES) V. The participants were divided into 4 groups: subjects with AMD, subjects without AMD, subjects with early AMD, and subjects with late AMD. Variables associated with endogenous and exogenous female hormone exposures were analyzed.
RESULTS
Among the 4,479 participants, 516 were found to have AMD and 3,963 were normal. There was no significant difference between the AMD and normal groups execpt for age in the risk analysis. Of the total 516 AMD participants, 488 had early AMD and 28 had late AMD. Women with AMD who had used oral contraceptives longer in the past had significantly higher odds of late AMD than early AMD (odds ratio [OR] = 1.013, 95% confidence interval [CI]: 1.002-1.024). Increasing number of children was also associated with decreased odds of late AMD (OR = 0.672, 95% CI: 0.506-0.893).
CONCLUSIONS
These findings suggest that exposure to endogenous and exogenous female hormones may influence the risk of AMD progression.

Keyword

Age-related macular degeneration; Female hormones; KNHANES V

MeSH Terms

Child
Contraceptives, Oral
Female*
Humans
Korea
Macular Degeneration*
Nutrition Surveys
Contraceptives, Oral

Reference

1. Mangione CM, Gutierrez PR, Lowe G, et al. Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol. 1999; 128:45–53.

2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 1992; 99:933–943.

3. Park KH, Song SJ, Lee WK, et al. The results of nation-wide registry of age-related macular degeneration on Korea. J Korean Ophthalmol Soc. 2010; 51:516–523.

4. Smith W, Mitchell P, Wang JJ. Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust N Z J Ophthalmol. 1997; 25:Suppl 1. S13–S15.

5. Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol. 1999; 6:125–143.

6. Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2000; 130:658–663.

7. Kaarniranta K, Machalińska A, Veréb Z, et al. Estrogen signalling in the pathogenesis of age-related macular degeneration. Curr Eye Res. 2015; 40:226–233.

8. Klein BE, Klein R, Jensen SC, Ritter LL. Are sex hormones associated with age-related maculopathy in women? The Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 1994; 92:289–295. discussion 295-7.

9. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration: A case-control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology. 2000; 107:2224–2232.

10. Klein BE, Klein R, Lee KE. Reproductive exposures, incident age-related cataracts, and age-related maculopathy in women: the beaver dam eye study. Am J Ophthalmol. 2000; 130:322–326.

11. Snow KK, Cote J, Yang W, et al. Association between reproductive and hormonal factors and age-related maculopathy in postmenopausal women. Am J Ophthalmol. 2002; 134:842–848.

12. Abramov Y, Borik S, Yahalom C, et al. The effect of hormone therapy on the risk for age-related maculopathy in postmenopausal women. Menopause. 2004; 11:62–68.

13. Edwards DR, Gallins P, Polk M, et al. Inverse association of female hormone replacement therapy with age-related macular degeneration and interactions with ARMS2 polymorphisms. Invest Ophthalmol Vis Sci. 2010; 51:1873–1879.

14. Freeman EE, Muñoz B, Bressler SB, West SK. Hormone replacement therapy, reproductive factors, and age-related macular degeneration: the Salisbury Eye Evaluation Project. Ophthalmic Epidemiol. 2005; 12:37–45.

15. Haan MN, Klein R, Klein BE, et al. Hormone therapy and age-related macular degeneration: the Women's Health Initiative Sight Exam Study. Arch Ophthalmol. 2006; 124:988–992.

16. Feskanich D, Cho EY, Schaumberg DA, et al. Menopausal and reproductive factors and risk of age-related macular degeneration. Arch Ophthalmol. 2008; 126:519–524.

17. Rim HT, Park SY, Yoon JS. Hormone replacement therapy and eye disease: KNHANES IV. J Korean Ophthalmol Soc. 2012; 53:1445–1450.

18. Yoon KC, Mun GH, Kim SD, et al. Prevalence of eye diseases in South Korea: data from the Korea National Health and Nutrition Examination Survey 2008-2009. Korean J Ophthalmol. 2011; 25:421–433.

19. Park SJ, Lee JH, Woo SJ, et al. Age-related macular degeneration: prevalence and risk factors from Korean National Health and Nutrition Examination Survey, 2008 through 2011. Ophthalmology. 2014; 121:1756–1765.

20. Centers for Disease Control and Prevention (CDC).Cigarette smoking among adults--United States, 1992, and changes in the definition of current cigarette smoking. MMWR Morb Mortal Wkly Rep. 1994; 43:342–346.

21. Muñoz B1, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. Arch Ophthalmol. 2000; 118:819–825.

22. Klein BE, Klein R, Lee KE. Incidence of age-related cataract: The Beaver Dam Eye Study. Arch Ophthalmol. 1998; 116:219–225.

23. Ogueta SB, Schwartz SD, Yamashita CK, Farber DB. Estrogen receptor in the human eye. Invest Ophthalmol Vis Sci. 1999; 40:1906–1911.

24. Munaut C, Lambert V, Noël A, et al. Presence of oestrogen receptor type beta in human retina. Br J Ophthalmol. 2001; 85:877–882.

25. Subbiah MT, Kessel B, Agrawal M, et al. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin endocrinol Metab. 1993; 77:1095–1097.

26. Calaf i Alsina J. Benefits of hormone replacement therapy--overview and update. Int J Fertil Womens Med. 1997; 42:Suppl 2. 329–346.

27. Subbiah MT. Mechanisms of cardioprotection by estrogens. Proc Soc Exp Biol Med. 1998; 217:23–29.

28. Kovacs WJ, Ojeda SR. Textbook of endocrine physiology. 6th ed. Oxford: Oxford University Press;2012. p. 264–291.

29. Cho HH. Use of hormonal contraception: In the case of coexisting medical disease. Korean J Obstet Gynecol. 2007; 50:1455–1467.

30. Seddon JM, Gensler G, Milton RC, et al. Association between C-reactive protein and age-related macular degeneration. JAMA. 2004; 291:704–710.

31. Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol. 2005; 123:774–782.

32. Cushman M, Legault C, Barrett-Conner E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999; 100:717–722.

33. Kwok S, Selby PL, McElduff P, et al. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. Clin Endocrinol (Oxf). 2004; 61:760–767.

34. Vessey MP, Hannaford P, Mant J, et al. Oral Contraception and eye disease: findings in two large cohort studies. Br J Ophthalmol. 1998; 82:538–542.